PE20230560A1 - Inhibidores de rip1k - Google Patents
Inhibidores de rip1kInfo
- Publication number
- PE20230560A1 PE20230560A1 PE2022002161A PE2022002161A PE20230560A1 PE 20230560 A1 PE20230560 A1 PE 20230560A1 PE 2022002161 A PE2022002161 A PE 2022002161A PE 2022002161 A PE2022002161 A PE 2022002161A PE 20230560 A1 PE20230560 A1 PE 20230560A1
- Authority
- PE
- Peru
- Prior art keywords
- rip1k
- inhibitors
- inhibitor compounds
- heteroaryl
- rip1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere a un compuesto de Formula I, en donde, el anillo B es heteroarilo de 5 o 6 miembros; X es CH2 u O; L es un heteroatomo, etc.; Z es alifaticoC1-10; arilo o heteroarilo, etc.; R1 es heterociclilo, -C?CH, etc.; R2, R3, R4 y R5 son H, alifaticoC1-10, etc.; Rb es OH, SH, etc.; Rc es alquilo C1-10, etc.; Rd es alifaticoC1-9 opcionalmente sustituido, etc.; Re es oxo, alcoxi, halo, etc.; m es 1 a 4; y n es 0, 1 o 2. Asimismo, se describen compuestos inhibidores de quinasa, tales como los compuestos inhibidores de la proteina quinasa 1 que interactua con el receptor (RIP1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004404P | 2020-04-02 | 2020-04-02 | |
| PCT/US2021/025598 WO2021203011A1 (en) | 2020-04-02 | 2021-04-02 | Rip1k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230560A1 true PE20230560A1 (es) | 2023-03-31 |
Family
ID=75747027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002161A PE20230560A1 (es) | 2020-04-02 | 2021-04-02 | Inhibidores de rip1k |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11584758B2 (es) |
| EP (1) | EP4126864A1 (es) |
| JP (1) | JP2023520046A (es) |
| KR (1) | KR20220161433A (es) |
| CN (1) | CN115867548A (es) |
| AR (1) | AR121717A1 (es) |
| AU (1) | AU2021246147B2 (es) |
| BR (1) | BR112022019492A2 (es) |
| CA (1) | CA3173432A1 (es) |
| CL (1) | CL2022002695A1 (es) |
| CO (1) | CO2022014137A2 (es) |
| CR (1) | CR20220492A (es) |
| DO (1) | DOP2022000215A (es) |
| EC (1) | ECSP22076856A (es) |
| IL (1) | IL296916A (es) |
| JO (1) | JOP20220246A1 (es) |
| MX (1) | MX2022012305A (es) |
| PE (1) | PE20230560A1 (es) |
| TW (1) | TW202204364A (es) |
| WO (1) | WO2021203011A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112979660A (zh) * | 2015-07-02 | 2021-06-18 | 豪夫迈·罗氏有限公司 | 二环内酰胺和其应用方法 |
| HRP20230909T1 (hr) | 2018-05-03 | 2023-12-08 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| RS64736B1 (sr) | 2018-05-03 | 2023-11-30 | Rigel Pharmaceuticals Inc | Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu |
| MX2022002717A (es) | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos. |
| WO2021046447A1 (en) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Heterocyclic rip1 kinase inhibitors |
| CA3169099A1 (en) * | 2020-02-28 | 2021-09-02 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| AU2023206890A1 (en) * | 2022-01-12 | 2024-08-22 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| WO2023138317A1 (zh) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
| TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| WO2016027253A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| WO2016128936A1 (en) | 2015-02-13 | 2016-08-18 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| CN112979660A (zh) | 2015-07-02 | 2021-06-18 | 豪夫迈·罗氏有限公司 | 二环内酰胺和其应用方法 |
| PL3362449T3 (pl) | 2015-10-13 | 2021-12-13 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową |
| EP3366684B1 (en) | 2015-10-23 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN109071504B (zh) | 2016-02-05 | 2022-03-08 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN110573504A (zh) | 2017-02-27 | 2019-12-13 | 葛兰素史克知识产权开发有限公司 | 作为激酶抑制剂的杂环酰胺 |
| US10590121B2 (en) * | 2017-06-29 | 2020-03-17 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| CN112074519B (zh) * | 2018-04-20 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物 |
| RS64736B1 (sr) | 2018-05-03 | 2023-11-30 | Rigel Pharmaceuticals Inc | Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu |
| HRP20230909T1 (hr) | 2018-05-03 | 2023-12-08 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| TW202019913A (zh) | 2018-06-26 | 2020-06-01 | 中國科學院上海有機化學研究所 | 細胞壞死抑制劑及其製備方法和用途 |
| CN109134448B (zh) | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| WO2020239074A1 (zh) | 2019-05-31 | 2020-12-03 | 南京明德新药研发有限公司 | 作为rip-1激酶抑制剂的双并环类化合物及其应用 |
| WO2021046447A1 (en) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Heterocyclic rip1 kinase inhibitors |
| MX2022002717A (es) | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos. |
| JP7395730B2 (ja) | 2019-11-07 | 2023-12-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ヘテロ環式ｒｉｐ１阻害化合物 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
-
2021
- 2021-03-31 AR ARP210100820A patent/AR121717A1/es unknown
- 2021-04-01 TW TW110112096A patent/TW202204364A/zh unknown
- 2021-04-02 BR BR112022019492A patent/BR112022019492A2/pt unknown
- 2021-04-02 WO PCT/US2021/025598 patent/WO2021203011A1/en active Application Filing
- 2021-04-02 JP JP2022559872A patent/JP2023520046A/ja active Pending
- 2021-04-02 CN CN202180038481.3A patent/CN115867548A/zh active Pending
- 2021-04-02 CR CR20220492A patent/CR20220492A/es unknown
- 2021-04-02 US US17/221,493 patent/US11584758B2/en active Active
- 2021-04-02 AU AU2021246147A patent/AU2021246147B2/en active Active
- 2021-04-02 CA CA3173432A patent/CA3173432A1/en active Pending
- 2021-04-02 PE PE2022002161A patent/PE20230560A1/es unknown
- 2021-04-02 EP EP21722607.5A patent/EP4126864A1/en active Pending
- 2021-04-02 MX MX2022012305A patent/MX2022012305A/es unknown
- 2021-04-02 KR KR1020227037796A patent/KR20220161433A/ko active Search and Examination
- 2021-04-02 IL IL296916A patent/IL296916A/en unknown
-
2022
- 2022-09-30 CL CL2022002695A patent/CL2022002695A1/es unknown
- 2022-09-30 DO DO2022000215A patent/DOP2022000215A/es unknown
- 2022-09-30 EC ECSENADI202276856A patent/ECSP22076856A/es unknown
- 2022-09-30 CO CONC2022/0014137A patent/CO2022014137A2/es unknown
- 2022-10-04 JO JOP/2022/0246A patent/JOP20220246A1/ar unknown
-
2023
- 2023-01-13 US US18/154,255 patent/US12043629B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230227469A1 (en) | 2023-07-20 |
| US12043629B2 (en) | 2024-07-23 |
| JP2023520046A (ja) | 2023-05-15 |
| WO2021203011A1 (en) | 2021-10-07 |
| US20210317135A1 (en) | 2021-10-14 |
| DOP2022000215A (es) | 2023-02-28 |
| MX2022012305A (es) | 2023-03-06 |
| KR20220161433A (ko) | 2022-12-06 |
| BR112022019492A2 (pt) | 2022-11-16 |
| CO2022014137A2 (es) | 2023-03-07 |
| IL296916A (en) | 2022-12-01 |
| AR121717A1 (es) | 2022-06-29 |
| CR20220492A (es) | 2023-02-09 |
| CA3173432A1 (en) | 2021-10-07 |
| JOP20220246A1 (ar) | 2023-01-30 |
| AU2021246147A1 (en) | 2022-10-20 |
| US11584758B2 (en) | 2023-02-21 |
| EP4126864A1 (en) | 2023-02-08 |
| CN115867548A (zh) | 2023-03-28 |
| AU2021246147B2 (en) | 2024-01-18 |
| ECSP22076856A (es) | 2023-02-28 |
| TW202204364A (zh) | 2022-02-01 |
| CL2022002695A1 (es) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230560A1 (es) | Inhibidores de rip1k | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR060562A1 (es) | Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas. | |
| RS52812B (en) | PYROLIDIN-2-DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS | |
| AR111279A1 (es) | Derivados heterocíclicos útiles como inhibidores duales de atx / ca | |
| CL2020002423A1 (es) | Nuevos compuestos heterocíclicos | |
| PE20230608A1 (es) | Quimioterapicos de eter macrociclico heteroaromatico | |
| UA122966C2 (uk) | Композиції з покращеним ефектом інгібування уреази, які містять триамід (тіо)фосфорної кислоти і додаткові сполуки, такі як аміни і барвники | |
| EA202092921A1 (ru) | Полициклическое производное карбамоилпиридона | |
| CO2019002692A2 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| AR119943A1 (es) | Compuestos heterocíclicos | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| PE20221083A1 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
| EA201270111A1 (ru) | Новые производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования акт(ркв) | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR121982A1 (es) | Moduladores del receptor ccr6 | |
| PE20240327A1 (es) | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
| CL2020002216A1 (es) | Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificación | |
| EA202090131A1 (ru) | Производные бензазепина | |
| CL2022000892A1 (es) | Derivados de 2–azaespiro[3.4]octano como agonistas de m4 | |
| PE20211088A1 (es) | Compuestos de isoxazolina para controlar plagas de invertebrados | |
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos |